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Systemic lupus erythematosus (SLE) is a chronic autoimmune 
disease characterized by multisystem involvement due to 
immune dysregulation. Neuropsychiatric systemic lupus 
erythematosus (NPSLE) includes neurological syndromes 
involving the central, peripheral and autonomic nervous sys- 
tem, as well as psychiatric syndromes observed in patients 
with SLE in which other causes have been excluded. The 
pathogenesis of NPSLE has been attributed to many differ- 
ent mechanisms. In particular, autoantibody-mediated vascu- 
lopathy seems to play a major role in the pathogenesis of the 
clinical features. Several autoantibody specificities have been 
reported in the serum and cerebrospinal fluid of NPSLE patients. 
Recently, we demonstrated an association between serum anti-
endothelial antibodies (AECA) and psychosis or depression in 
SLE patients, strengthening the notion of a possible role of this 
class of autoantibodies in the pathogenesis of the disease. The 
study of these autoantibodies could be a useful diagnostic and 
prognostic tool in patients with NPSLE.
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aBstract:
KeY wOrds:
s ystemic lupus erythematosus (SLE) is a chronic autoim-mune disease characterized by multisystem involvement 
with a broad spectrum of clinical manifestations due to immune 
dysregulation causing production of autoantibodies, generation 
of circulating immune complexes, and activation of the comple-
ment system. Neuropsychiatric manifestations in SLE (NPSLE) 
include psychiatric and neurologic syndromes involving the 
central, peripheral and autonomic nervous system observed in 
patients with SLE in which other causes have been excluded. 
These manifestations can precede the onset of SLE or occur at 
any time during the course of the disease [1]. They may present 
as single or multiple neurologic events in the same individual. 
A large variety of neuropsychiatric disorders are reported in 
NPSLE patients, including depression, psychosis, anxiety, mood 
disorders, cognitive dysfunction, memory deficit, delirium/
encephalopathy, and acute confusional states. The reported 
prevalence of psychiatric disorders in SLE ranges from 14% to 
75% [2], reflecting the different methods of patient selection and 
assessment, the different professional orientation of clinicians, 
and the lack of an accepted consensus for diagnosing active 
NPSLE. Moreover, it appears that neuropsychiatric syndromes 
could even be prevalent in pediatric patients with SLE, manifest-
ing early in the disease course and with significant morbidity. 
In 1999, the American College of Rheumatology (ACR) 
ad hoc committee, adopting the terminology of DSM IV, 
defined 19 NPSLE syndromes [3] [Table 1]. However, due to 
the reported inadequate performance of the proposed ACR 
criteria, as well as difficulties in differentiating SLE patients 
from controls and neuropsychiatric SLE patients from other 
SLE patients, some authors criticized the lack of criteria based 
on neuropathogenic features. Since no single diagnostic test is 
sensitive or specific for NPSLE, the proper diagnosis depends 
on the combination of physical examination, brain imaging, 
immunoserological, psychiatric and neuropsychological tests, 
and presence of lupus disease activity. Recommendations for 
the use of computed tomography (CT), standard magnetic 
resonance imaging (MRI), angiography, electroencephalog-
raphy (EEG), echocardiography, and duplex ultrasound were 
included. In particular, MRI was demonstrated to be useful. 
table 1. NPSLE syndromes defined by the ACR committee in 1999
central nervous system peripheral nervous system
• Aseptic meningitis
• Cerebrovascular disease
• Demyelinating syndrome
• Headache (including migraine and 
benign intracranial hypertension)
• movement disorder (chorea)
• myelopathy
• Seizure disorders
• Acute confusional state
• Anxiety disorder
• Cognitive dysfunction
• mood disorder
• Psychosis
• Acute inflammatory demyelinating 
polyradiculoneuropathy (Guillain-
Barré syndrome)
• Autonomic disorder
• mononeuropathy, single/multiplex
• myasthenia gravis
• Neuropathy, cranial
• Plexopathy
• Polyneuropathy
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The most common findings are small spot T2-hyperintense 
lesions (gliotic foci) in the white subcortical matter, mainly 
concentrated in frontal-parietal regions. Other signs can be 
cortical atrophy, periventricular lesions, dilation of ventricu-
lar chambers, and ischemic lesions [4]. While gadolinium is 
extremely useful for the characterization of acute inflammatory 
lesions, only 19% of NPSLE patients are recognized by MRI. On 
the other hand, single photon emission-computed tomography 
(PET-CT) and in vivo magnetic resonance spectroscopy have 
demonstrated a sensitivity of almost 100% in active NPSLE, but 
low specificity, compared to MRI. 
Neuropsychological tests have been standardized to exam-
ine five major areas: general intelligence, verbal learning/
memory, visual-spatial skills, psychomotor speed/manual 
dexterity, and attention/mental flexibility. Furthermore, most 
of the immunochemical tests studied in NPSLE are consid-
ered investigational, except testing for antiphospholipid anti-
bodies (aPL) and anti-ribosomal P antibodies (anti-P), which 
seem to play an important role in the pathogenesis of NPSLE. 
patHOgenesis
Over the years, several groups have expanded our knowledge on 
the nature of NPSLE pathogenesis. Multiple mechanisms were 
proposed, including antibodies, vasculitis, thrombosis, hemor-
rhage, hypertension, accelerated atherosclerosis, choroid plexus 
dysfunction, neuroendocrine immune effects, direct central 
nervous system (CNS) tissue injury, and cytokine-mediated 
damage [2]. Rhiannon [5] distinguished primary from second-
ary mechanisms. The primary mechanisms include vascular 
occlusion/hemorrhage, autoantibody-mediated (primarily 
anti-neuronal antibodies), choroid plexus dysfunction, cyto-
kine effects, neuroendocrine-immune imbalances, and direct 
neural tissue injury (mediated by oxidative stress, excitatory 
amino acid toxicity and matrix metalloproteinase injury). On 
the other hand, secondary mechanisms include infections, 
medications, thrombotic throm-
bocytopenic purpura, hyperten-
sion, uremia, fever, electrolyte 
imbalances, thyroid disease, berry 
aneurysm, fibromyalgia, cerebral lymphoma, subdural hema-
toma, atherosclerotic cerebrovascular accident/stroke (CVA), 
reactive depression, sleep apnea, and another primary psy-
chiatric or neurologic disease. A variety of autoantibodies has 
been implicated in the pathogenesis of the disease [Table 2]. 
These were found in the serum and cerebrospinal fluid (CSF). 
Anti-neuronal antibodies are directed against brain synapses, 
neurofilaments, GFAP, MAP-2, and NMO. Non-neural-specific 
antibodies include anti-P, antiphospholipid antibodies (aPL), 
anti-dsDNA, anti-N-methyl-D-aspartate (NMDA, also known 
as anti-NR2), anti-gangliosides (GM-10) lymphocytotoxic anti-
bodies, and anti-endothelial cell antibodies (AECA). 
tHe rOle Of autOantiBOdies 
The reported prevalence of autoantibodies in NPSLE is highly 
variable, depending on different ethnic background, sensitiv-
ity and specificity of the assays, and the time of the analysis 
with respect to the manifestation of the clinical event. In 1979, 
Bresnihan et al. [6] first suggested the potential pathogenic 
relevance of anti-neuronal, anti-P and anti-glial fibrillary acid 
proteins, and aPL in the psychiatric manifestation of SLE. More 
recently AECAs have been studied and correlated with the 
occurrence of such clinical events. The etiopathogenic role of 
autoantibodies in NPSLE remains unclear. Anti-neuronal anti-
bodies can be found in the brain of NZB/W mice, supporting a 
direct pathogenic role. Given their higher reactivity in the CSF 
of patients with NPSLE, an intrathecal synthesis has been pro-
posed. Nevertheless, the finding of 
cross-reactivity of lymphocytotoxic 
antibodies, anti-neuronal antibod-
ies and mycobacterial glycolipids, 
together with impairment of the blood-brain barrier (BBB) 
frequently observed in NPSLE, may suggest the hypothesis of 
an extrathecal synthesis of the autoantibodies. 
autOantiBOdies tO Brain cOmpOnents
• anti-riBOsOmal p prOtein p0 antiBOdies (anti-p)
Anti-P are directed against three phosphoproteins located on 
the larger 60 S subunit of eukaryotic ribosomes (P0, P1, P2). The 
prevalence of anti-P in SLE patients ranges from 6% to 36% [7] 
and their specificity for SLE was recently estimated at 99.4% [8]. 
Only a few studies have noted their presence in other diseases, 
a proper and quick diagnosis is 
essential for managing neuropsychiatric 
manifestations in sle patients 
table 2. Autoantibodies associated with NPSLE
autoantibodies reference
Anti-ribosomal P protein P0 (anti-P) [7-15]
Anti-glial fibrillary acid protein antibodies (anti-GFAP) [13]
Anti-N-methyl-D-aspartate (NmDA) antibodies (anti-NmDA) [13,15]
Antiphospholipid antibodies (aPL) [13,16-20]
Anti-Nedd5 antibodies (anti-Nedd5) [21]
Anti-NR2 glutamate receptor (anti-NR2) [14]
Anti-endothelial cells (AECA) [13,19,25-27]
Anti-neuronal [33]
Anti-brain-reactive antibodies (BRAA) [34]
Anti-microtubule-associated protein 2 (anti-mAP-2) [35]
Anti-ganglioside (AGA) [36]
Anti-serum lymphocytotoxic [37]
Anti-neurofilament [38]
Anti-Ro/SSA [39]
Anti-Sm [40]
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Furthermore, it was shown that sera showing reactivity to 
DNA and NMDA receptor obtained from lupus patients can 
elicit cognitive impairment when intravenously injected in 
mice [16]. 
• antipHOspHOlipid antiBOdies (apl)
Antiphospholipid antibodies are a heterogeneous group 
of antibodies directed against anionic phospholipids, 
phospholipid-binding plasma proteins, and phospholipid-
protein complexes [17]. The association between aPL and 
NPSLE was first reported in 1984, and it is clear today that 
their main pathogenic effect results in thrombosis. aPL may 
contribute to neurologic damage by reacting with brain cells 
via β2-glycoprotein I (β2GPI) interaction. We have demon-
strated the expression of β2GPI mRNA by astrocytes and 
neuronal and endothelial cells, suggesting that these cells can 
be a target of autoantibodies in antiphospholipid syndrome 
(APS) [18,19]. No significant association was found between 
aPL and AECA [13], although it has been postulated that 
AECA reactivity might be partly caused by the binding to 
a complex of β2GPI with phospholipids on endothelial cells. 
Nonetheless, Meroni et al. [20] found AECA positivity in 5 of 
14 SLE patients with CNS involvement. The authors demon-
strated that aPL and AECA are associated with neurological 
manifestations in SLE patients. 
In another study, human endothelial cells were incubated 
with mouse AECA monoclonal antibodies, and the translocation 
of phosphatidylserine (PS) was established through the bind-
ing of annexin V, which binds specifically to PS. A rabbit β2GPI 
antibody and biotin-conjugated F(ab’)2 aPL derived from three 
patients were also used to detect β2GPI on the cells. The authors 
found that 20–36% of the cells expressed anionic PL following 
incubation with AECAs, suggesting that some of these may be 
pathogenic and may even have the potential to induce produc-
tion of aPL [21]. These in vivo obser-
vations were further validated by 
studies conducted on mouse models 
of APS, showing the development of 
neurological dysfunction and hyperactive behavior associated 
with aPL, anti-β2GPI and AECA after passive immunization 
with human anticardiolipin (anti-CL) monoclonal antibodies. 
Interestingly, we recently investigated whether cognitive impair-
ment in SLE is associated with serum autoantibodies, disease 
activity and chronic damage. Antinuclear antibodies (ANA), 
anti-dsDNA, anti-CL, anti-β2GPI, anti-P, AECA and anti-Nedd5 
antibodies were evaluated, and SLEDAI-2000 and SLICC were 
used to assess disease activity and chronic damage, respectively. 
We reported a significant association between aPL, disease activ-
ity, and chronic damage with cognitive dysfunction in SLE. In 
particular, anti-CL IgM were found associated with visual-spatial 
domain impairment (r = 0.331, P = 0.005) [22], strengthening 
the view of aPL involvement in NPLE manifestations.
e.g., autoimmune hepatitis and autism. The association between 
anti-P and lupus psychosis was first described by Bonfa and co-
workers [9]. Yoshio et al. [10] suggested the existence of a strong 
association between immunoglobulin (Ig) G and IgM anti-P 
with CNS disease, excluding lupus psychosis, in SLE patients. 
Moreover, several studies have demonstrated a decrease in ver-
bal memory, psychomotor speed, and olfaction in SLE patients 
compared with healthy subjects, correlating with disease activ-
ity and CNS involvement. Interestingly, a relationship between 
smell impairment and anti-P has been observed. These data 
were confirmed by a recent study in which affinity-purified 
human anti-P were injected intracerebroventricularly (ICV) 
in mice [11]. The results showed that these antibodies induce 
both depression-like behavior and impaired olfactory function. 
The ribosomal P0 protein has been identified by molecular 
cloning strategy as an endothelial autoantigen in SLE patients 
[12]. Moreover, purified IgG anti-P derived from patients with 
SLE seems to activate human umbilical vein endothelial cells 
(HUVEC), as well as monocytes, leading to intrathecal B lym-
phocyte activation upon increased interleukin-6 (IL-6) produc-
tion. In our cohort, 7.8% of SLE patients were anti-P positive 
but no association with psychiatric disturbances was found [13]. 
Remarkably, all patients with lupus psychosis tested seronega-
tive for these autoantibodies. Finally, a significant difference was 
documented between the enzyme-linked immunosorbent assay 
(ELISA) kits used for the detection of anti-P; hence, the need 
for standardization of laboratory assays in the future which will 
enable better assessment of both the presence of anti-P and their 
clinical significance [14]. 
• anti-glial fiBrillarY acid prOtein antiBOdies (anti-gfaps)
The GFAPs are 50 kDa intracytoplasmic filamentous proteins 
of the astrocytes, which stabilize the cytoskeleton and main-
tain astrocyte cell shape through the interaction with nuclear 
and plasma membranes. At present, 
these are the most specific markers 
to recognize cells of astrocytic ori-
gin in both normal and pathologic 
conditions. GFAPs are up-regulated in gliotic hypertrophy and 
perivascular inflammation of Alzheimer’s disease and multiple 
sclerosis. In addition, anti-GFPA antibodies were observed in 
patients with these conditions. Recently, it was demonstrated 
that anti-GFAPs are increased in the CSF of NPSLE patients. 
Although we found anti-GFPAs in 15% of sera from our SLE 
cohort, no significant correlations with neurologic or psychiatric 
morbidity were observed. 
• anti-n-metHYl-d-aspartate (nmda) antiBOdies
DeGiorgio et al. [15] demonstrated in vitro that a subset of 
anti-DNA antibodies cross-reacts with N-methyl-D-aspartate 
(NMDA) and induces neuronal cell injury. These autoanti-
bodies can be found occasionally in the CSF of SLE patients. 
antiphospholipid and anti-p ribosomal 
antibody testing can be useful in  
npsle diagnosis
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and monocytes. AECAs recognize antigens expressed constitu-
tively, other cryptic antigens that are cytokine-induced, as well 
as adhesion molecules. Even the human leucocyte antigen class 
I and II (HLA) determinants as well as extracellular matrix com-
ponents (i.e., collagen types II, IV and VII, vimentin or laminin) 
constitute endothelial cell antigens. Autoantibodies against these 
antigens have been reported in systemic sclerosis (SSc) and SLE. 
Several molecules could bind to endothelial cells and become 
the so-called planted target antigens for AECA via presumed 
charge-mediated mechanisms, a DNA-histone bridge, or a spe-
cific receptor. Some examples are myeloperoxidase, DNA and 
β2GPI, which might adhere to endothelial cells incubated with 
patient’s sera. AECAs can recognize antigens present solely in 
microvascular but not macrovascular endothelial cells. It seems 
that phenotypic and functional differences – such as nutritional 
requirements and responses to growth and migration stimuli 
– between endothelial cell antigens from microvascular and 
macrovascular sites may be responsible for this phenomenon. 
Thus, the evaluation of endothelial cells from vessels of different 
sizes seems advised in AECA assays. 
The development of techniques to identify new antigens 
targeted by AECAs has allowed the building of expression 
libraries of complementary DNA to messenger RNA extracted 
from endothelial cells and then transfected into prokaryotic or 
eukaryotic cells. Belizna et al. [26] characterized the putative 
target antigens for AECA, recognizing a role for EC-specific 
plasminogen activator inhibitor, ribosomal P protein P0, ribo-
somal protein L6, elongation factor 1a, adenylcyclase-associated 
protein, DNA replication licensing factor, profilin II, and human 
EC-associated lupus autoantigens 1 and 255. Furthermore, it was 
shown that the levels of these antibodies directly correlate with 
AECA levels and clinical findings in patients affected with SLE 
and systemic vasculitis. Another technique, two-dimensional 
electrophoresis, seems to be promising. Indeed, combined with 
western blot analysis using protein 
extracts from a hybridoma cell 
line, it enables the identification 
of antigens such as calreticulin, 
tubulin, vimentin and Hsp70. Recently, RLIP76 was identi-
fied as a new AECA autoantigen. RLIP76 catalyzes the ATP-
dependent transport of glutathione (GSH) conjugates including 
GS-4-hydroxy-t-2,3-nonenal (GS-HNE) [27]. ELISA detected 
IgG specific to RLIP76 in 30% of patients with Behçet disease 
(BD), 17% with SSc, 21% with rheumatoid arthritis (RA), and 
30% with SLE, but in none of the sera from patients with mono-
nucleosis or from healthy subjects. These results suggest that 
RLIP76 may play a major role in endothelial dysfunction in 
distinct autoimmune diseases. 
Another newly discovered endothelial antigen is RABPT5, 
an essential and rate-limiting component of early endosomal 
fusion that regulates the release of neurotransmitter and 
neuritis outgrowth. RABPT5 is massively redistributed in 
• anti-nedd5 antiBOdies
Nedd5 is a septin that plays an essential role in cytokinesis in 
mammalian cells. During apoptosis, Nedd5 moves from the 
cytoplasm to the cell surface, a process that might explain its 
increased immunogenity [23]. Although anti-Nedd5 autoanti-
bodies are not specific to SLE, they are significantly associated 
with NPSLE and could serve as an immunological marker of 
psychiatric manifestations. 
• anti-nr2 glutamate receptOr 
As mentioned earlier, in 2001 DeGiorgio et al. [15] showed that 
anti-dsDNA autoantibodies from sera of SLE patients cross-
react with NR2 glutamate receptors and mediate apoptotic death 
of neurons in vivo as well as in vitro. Following these results, it 
was demonstrated that IgG anti-NR2 antibodies in the CNS of 
SLE patients induce EC activation. Moreover, by activating the 
nuclear factor kB (NF-κB) signaling pathway, these antibodies 
may lead to inflammation of the blood-brain barrier, thereby 
possibly initiating the pathogenesis of NPSLE [24]. Most studies 
found anti-NR2 antibodies in blood in approximately one-third 
of SLE patients, at a higher ratio than in patients with other 
autoimmune diseases. Anti-NR2 antibodies are observed more 
often in the CSF of NPSLE patients than in the CSF of patients 
without autoimmune, neurologic or psychiatric diseases. 
Moreover, SLE patients with acute CNS manifestations or sep-
tic meningitis may present higher intrathecal concentrations of 
anti-NR2 antibodies than SLE patients hospitalized for other 
reasons. Nonetheless, their role in cognitive dysfunction and 
psychiatric manifestation of SLE is still under debate. 
aeca and npsle
AECAs were first described in 1971 by Lindqvist and Osterland 
[25] in chronic tuberculosis. These antibodies target a hetero-
geneous group of antigens directed 
against different structural endo-
thelial proteins, ranging from 10 
[25] to 200 KDa, as well as adher-
ing to endothelial cells detected in a variety of diseases sharing 
vessel wall damage. AECAs have been detected in healthy indi-
viduals, as well as in autoimmune and systemic inflammatory 
diseases including nervous system diseases. The prevalence of 
AECA in SLE patients ranges from 17% to 75%. We recently 
reported an association between serum AECA with psychosis 
and depression in patients with SLE [13], strengthening the view 
of a possible role of AECA in the development of psychiatric 
disorders. 
• antigen cHaracterizatiOn
AECAs are generally not specific for endothelial cells and a 
variety of antigens can be found on different substrates. AECA 
antigenic specificity is also observed in fibroblasts, leukocytes 
aeca were shown to be highly associated 
with npsle and their pathogenic role  
has been demonstrated 
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the cytoplasm of endothelial cells during apoptosis, possibly 
explaining its immunogenicity. Anti-RABPT5 antibodies bind 
and hinder the function of the RABPT5 protein in the neu-
rons. This chain of events leads to the inhibition of endosomal 
membrane fusion which performs a protective function against 
amyloid deposit. In addition, anti-RABPT5 might cross-react 
with neurocrescin, hampering its ability to regenerate damaged 
neurons, suggesting a pathogenic role for these antibodies. 
There is evidence for a specific clone of AECA directed to actin, 
particularly in patients with atherosclerosis. It is well known 
that the humoral immune response to endothelium has a piv-
otal role in the development of atherosclerosis. In a previous 
study by our group [22], we performed immunoscreening of a 
human umbilical artery endothelial cells (HUAEC) expression 
library with IgG from two patients with carotid atherosclerosis 
and identified a clone specific to actin. The actin-specific IgG 
reactivity was evaluated in patients with carotid atherosclerosis, 
and the results were compared with those obtained from SLE 
and T1DM patients and from healthy subjects. Actin-specific 
IgG reactivity was detected in a significantly higher percentage 
of sera from patients with atherosclerosis and SLE than from 
healthy subjects (26% and 39%, respectively, vs. 5% of healthy 
subjects; P = 0.012 and P < 0.0001). Therefore, actin can repre-
sent an autoantigenic molecule of potential clinical interest in 
carotid atherosclerosis and SLE vasculitis.
Another endothelial antigen targeted by AECA is Sip-1. This 
is a nuclear splicing factor containing an arginine/serine-rich 
domain and a RNA-binding motif probably involved in tran-
scription and pre-mRNA splicing. In a previous study, we dem-
onstrated that IgG, IgM, and IgA specific to factor Sip1 C-ter 
were detectable in patients with several autoimmune diseases 
characterized by the presence of serum AECA, such as BD, SLE, 
SSc, and primary vasculitis as well as in patients with diseases 
that share some clinical features with BD (inflammatory bowel 
disease and uveitis). We also found that IgM immunoreactivity 
was significantly higher in patients with BD and in patients 
with primary vasculitis than in the other tested groups [28]. 
Finally, the presence of AECA has even been demonstrated in 
a small percentage of healthy individuals. The so-called natural 
AECAs (NA) include polyreactive IgM, IgG, and/or IgA, which 
recognize a restricted and conserved set of endothelial antigens 
and express low affinity for their target antigens in most of the 
cases. NA may bind to circulating molecules such as hormones 
and cytokines, as well as lymphocytes and endothelial cells. 
Normal IgG interacts with living endothelial cells and is internal-
ized with a mechanism involving microtubules and resembling 
that of ligand-receptor internalization. IgG-endothelial cell 
interaction appears to be dependent on the variable region of 
antibodies and is followed by modifications of endothelial cell 
function. Natural AECAs increase anti-inflammatory properties 
of endothelial cells through the selective inhibition of thrombox-
ane A2, endothelin and metalloproteinase-9 secretion, as well 
as through the inhibition of endothelial cell pro-inflammatory 
response to tumor necrosis factor-alpha (TNFα) [29]. Recently, 
Servettaz et al. [30] identified the targets of NA in cytoskeletal 
proteins (β-actin, vimentin, α-tubulin), prolyl-4 hydroxylase 
β-subunit (a member of the disulfide isomerase family) and two 
glycolytic enzymes (glyceraldehyde-3-phosphate-deshydroge-
nase and α-enolase). All these are ubiquitary proteins implicated 
in cell-cycle regulation, membrane fusion, microtubule bundling, 
nuclear RNA export and DNA replication and repair, regulation 
of coagulation (α-enolase is an activator of plasminogen), and 
cell growth. Thus, NA may participate in host defense against 
pathogens by opsonization, contributes to the clearance of senes-
cent cells and immune complexes, and/or exerts anti-inflamma-
tory and anti-thrombotic properties, together with preventing 
endothelial cell activation by TNFα. Finally, these antibodies may 
play a role in fetal tolerance and impaired immune regulation, 
such as diminished levels of serum IgM-AECA detected in SLE 
patients that may contribute to impaired reproductive function 
commonly seen in SLE [31].
aeca: multiple mecHanisms fOr a  
pleiOtrOpic plaYer 
AECA might contribute to the pathogenesis of systemic vascu-
litis and vasculitis-associated diseases through a) activation of 
ECs, b) direct cytotoxic effect due to complement-dependent 
cytotoxicity or indirect cytotoxic effect secondary to antibody-
dependent cytotoxicity, c) induction of coagulation, and d) 
induction of apoptosis through the binding of phospholipids 
or heat-shock protein 60. Mechanisms of disease are summa-
rized in Figure 1. Del Papa and colleagues [32] demonstrated 
that AECAs can activate ECs by inducing the expression of 
adhesion molecules, such as E-selectin, intercellular adhe-
sion molecule 1 and vascular cell adhesion molecule 1, in a 
dose-dependent fashion. Moreover, AECAs can stimulate the 
production of cytokines, including interleukin (IL)-1b and 
IL-8, and chemokines such as monocyte-chemotactic protein 
1. Specifically, AECAs might promote a pro-inflammatory 
and pro-adhesive EC phenotype through the induction of 
the mitogen-activated protein kinase cascade. Additionally, a 
number of cytokines, e.g., TNFα, can in turn activate NF-κB 
pathway and c-Jun N-terminal kinase-mitogen-activated 
protein kinases. The result is increased leukocyte adhesion to 
endothelial cells induced by the release of endothelium-derived 
mediators rather than complement-dependent cell-mediated 
EC damage. AECAs have been associated with thrombosis, 
for instance by promoting the production of tissue factor (TF) 
and thereby favoring coagulation. It was also demonstrated that 
AECA is a genuine promoter of TF synthesis. Accordingly, high 
plasma levels of von Willebrand factor, thrombomodulin and 
tissue plasminogen activator (TPA) were detected in patients 
with SLE. Furthermore, TF activity, TF antigen and TF mRNA 
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were dose-dependent on AECA titers. Taken together, these 
data strongly suggest that activation of ECs leads to a procoagu-
lant status. Furthermore, anti-heparin antibodies (AHA) can 
be found in patients with SLE and seem to correlate with renal 
and neurological disease. AHAs exert complement-dependent 
cytotoxicity on ECs and form immune complexes with hepa-
rin, one of the major glycosaminoglycans in ECs. It has been 
reported that the binding of AECA to EC can provoke cleavage 
and release of heparan sulphate and promote pro-inflammatory 
and procoagulant processes and apoptosis. This effect is spe-
cific for AECA since elution studies failed to show inhibition 
with anti-CL, anti-DNA, hyaluronate or chondroitine sulphate. 
AECAs also seem to correlate with anti-CL in SLE patients. 
Indeed, aPL can contribute to a pro-inflammatory and proco-
agulant endothelial phenotype by interfering with the binding 
of annexin V, synthesis of endothelin I, induction of apoptosis 
and the protein containment/surveillance system. AECAs may 
increase the expression of negative ionic phospholipids such 
as phosphatidylserine (PS) on the surface of ECs, leading to 
increased binding of anti-CL. It was reported that AECAs from 
the sera of patients with vasculitis can trigger the translocation 
of anionic phospholipids, most notably PS, from the inner to 
the outer leaflet of the plasma membrane, and consequently 
the binding of FITC-conjugated annexin V. Interestingly, the 
accessibility of PS to annexin V was restricted to those cells 
recognized by AECA. Moreover, autoantibodies targeting 
the heat-shock protein 60 (Hsp60) were recently identified in 
patients with SLE. These bind endothelial cells and induce PS 
exposure, followed by apoptosis, thus providing a target for 
anti-PS. Fas receptor can also be targeted by AECA; however, 
further activation does not seem to be a prerequisite for AECA-
mediated apoptosis of ECs, and other authors have reported 
Fas-independent apoptosis. Finally, AECA could exert a direct 
cytotoxic effect through complement-dependent cytotoxicity, 
especially when ECs are stimulated with IL-1 or TNFα.
detectiOn metHOds 
AECAs were identified using mouse frozen kidney sections 
as the substrate in the standard indirect immunofluorescence 
(IF) technique. The binding of AECA was demonstrated in the 
target cells through the F(ab)2 portion, rather than the Fc por-
tion of the antibody. The most frequently used AECA detection 
methods are IF, ELISA, immunoblotting, radioimmunoassay, 
fluorescence-activated cell sorting, immunoprecipitation, com-
plement-dependent cytotoxicity and the antibody-dependent 
cell-mediated cytotoxicity. Immunofluorescence was the first 
technique to be developed, but today AECAs are only rarely 
tested with this method. ELISA, performed on HUVEC as 
substrate, is the most commonly used. Other substrates can be 
employed, such as cell membrane extracts, cells from renal or 
medullary microvessels, and hybridoma cell lines. Generally, 
confluent EC monolayers are fixed before testing to avoid non-
specific IgG-binding loss of cells. Nevertheless, fixation induces 
figure 1. mechanism of damage 
mediated by AECA in NPSLE
AECA might contribute to the 
pathogenesis of systemic vasculitis and 
vasculitis-associated diseases through 
different mechanisms. They can activate 
ECs by inducing the expression of 
adhesion molecules, such as E-selectin, 
intercellular adhesion molecule 1 (ICAm-
1) and vascular cell adhesion molecule 1 
(VCAm-1), and stimulating the production 
of cytokines, including interleukin IL-1 
and IL-8, and chemokines, such as 
monocyte-chemotactic protein 1 (mCP-1), 
thus increasing leukocyte adhesion to 
ECs. Additionally, a number of cytokines, 
such as tumor necrosis factor-alpha 
(TNFα), can in turn activate the nuclear 
factor kB (NFkB) pathway. AECAs can 
also enhance the production of tissue 
factor (TF) and high plasma levels of von 
Willebrand factor (vWF), hence promoting 
thrombosis. Finally, AECAs can target Fas 
receptor or exert direct cytotoxic effect 
through CDC, especially when ECs are 
stimulated with IL-1 or TNFα 
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permeabilization of EC membranes, which may allow AECA 
cross-reaction against intracellular compounds. To avoid these 
artifacts, ELISA with unfixed EC can be used. False-negative 
AECA results can be due to the lack of expression of certain 
target antigens on a specific substrate. For this reason, it has 
been recommended that several EC substrates be used simulta-
neously. False-positive AECA could occur owing to endogenous 
antibodies, such as anti-β2GPI, reacting with fetal calf serum 
(FCS) proteins from culture medium coated on ELISA plates. 
This error could be avoided by antibody absorption in FCS-
containing dilution buffer or by washing cells of FCS before 
plating. Finally, there is a subpopulation of AECA that is likely 
to react with extracellular matrix components, such as collagen 
type II, IV, VII, and laminin, leading to false-positive results. 
cOnclusiOns
In the management of NPSLE, identification of the clinical 
features as well as achievement of early diagnosis is crucial 
for determining the optimal treatment. Several mechanisms 
are involved in the pathogenesis of these disorders. Most are 
autoantibody-dependent or related, and there is considerable 
evidence that AECAs might play a key role in these processes. 
Nevertheless, low specificity, the lack of standardized detection 
methods, and the possible presence of NA secondary to SLE 
polyclonal B cell activation limit the use of AECAs as diagnos-
tic and prognostic markers. Clearly, further studies are neces-
sary for fully understanding their role in SLE clinical practice.
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In type 2 diabetes, hyperglycemia is present when an increased 
demand for insulin, typically due to insulin resistance, is not 
met as a result of progressive pancreatic beta cell dysfunction. 
This defect in beta cell activity is typically characterized by 
impaired insulin biosynthesis and secretion, usually ac- 
companied by oxidative and endoplasmic reticulum (ER) 
stress. Hasnain et al. demonstrated that multiple inflammatory 
cytokines elevated in diabetic pancreatic islets induce beta 
cell oxidative and ER stress, with interleukin-23 (IL-23), IL-24 
and IL-33 being the most potent. Conversely, the authors show 
that islet-endogenous and exogenous IL-22, by regulating 
oxidative stress pathways, suppresses oxidative and ER stress 
caused by cytokines or glucolipotoxicity in mouse and human 
beta cells. In obese mice, antibody neutralization of IL-23 
or IL-24 partially reduced beta cell ER stress and improved 
glucose tolerance, whereas IL-22 administration modulated 
oxidative stress regulatory genes in islets, suppressed ER 
stress and inflammation, promoted secretion of high quality 
efficacious insulin and fully restored glucose homeostasis 
followed by restitution of insulin sensitivity. Thus, therapeutic 
manipulation of immune regulators of beta cell stress reverses 
the hyperglycemia central to diabetes pathology. 
Nature med 2014; 29: 1417
Eitan Israeli
capsule
glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate 
beta cell stress
The incidences of chronic inflammatory disorders have 
increased considerably over the past three decades. Recent 
shifts in dietary consumption may have contributed impor- 
tantly to this surge, but how dietary consumption modulates 
inflammatory disease is poorly defined. Pstpip2cmo mice, 
which express a homozygous Leu98Pro missense mutation 
in the Pombe Cdc15 homology family protein PSTPIP2 
(proline-serine-threonine phosphatase interacting protein 
2), spontaneously develop osteomyelitis that resembles 
chronic recurrent multifocal osteomyelitis in humans. Recent 
reports demonstrated a crucial role for interleukin-1β (IL-1β) in 
osteomyelitis, but deletion of the inflammasome components 
caspase-1 and NLRP3 failed to rescue Pstpip2cmo mice from 
inflammatory bone disease. Thus, the upstream mechanisms 
controlling IL-1β production in Pstpip2cmo mice remain to be 
identified. In addition, the environmental factors driving IL-1β-
dependent inflammatory bone erosion are unknown. Lukens 
et al. have shown that the intestinal microbiota of diseased 
Pstpip2cmo mice was characterized by an outgrowth of 
Prevotella. Notably, Pstpip2cmo mice that were fed a diet rich in 
fat and cholesterol maintained a normal body weight, but were 
markedly protected against inflammatory bone disease and 
bone erosion. Diet-induced protection against osteomyelitis 
was accompanied by marked reductions in intestinal Prevotella 
levels and significantly reduced pro-IL-1β expression in distant 
neutrophils. Furthermore, pro-IL-1β expression was also 
decreased in Pstpip2cmo mice treated with antibiotics, and in 
wild-type mice that were kept under germ-free conditions. The 
authors further demonstrate that combined deletion of caspases 
1 and 8 was required for protection against IL-1β-dependent 
inflammatory bone disease, whereas the deletion of either 
caspase alone or of elastase or neutrophil proteinase 3 failed 
to prevent inflammatory disease. Collectively, this work reveals 
diet-associated changes in the intestinal microbiome as a crucial 
factor regulating inflammasome- and caspase-8-mediated 
maturation of IL-1β and osteomyelitis in Pstpip2cmo mice. 
Nature 2014: 516: 246
Eitan Israeli
capsule
dietary modulation of the microbiome affects autoinflammatory disease
